Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05943496 |
| Title | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | OHSU Knight Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| OHSU Knight Cancer Institute | RECRUITING | Portland | Oregon | 97239 | United States | Details |